Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Guided Therapeutics (GTHP) Gross Profit (2016 - 2025)

Guided Therapeutics' Gross Profit history spans 16 years, with the latest figure at $458000.0 for Q4 2025.

  • On a quarterly basis, Gross Profit rose 23000.0% to $458000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $572000.0, a 28500.0% increase, with the full-year FY2025 number at $571000.0, up 28450.0% from a year prior.
  • Gross Profit hit $458000.0 in Q4 2025 for Guided Therapeutics, up from $35000.0 in the prior quarter.
  • Over the last five years, Gross Profit for GTHP hit a ceiling of $458000.0 in Q4 2025 and a floor of -$79000.0 in Q4 2022.
  • Historically, Gross Profit has averaged $35125.0 across 5 years, with a median of $4000.0 in 2022.
  • Biggest five-year swings in Gross Profit: plummeted 292.68% in 2022 and later surged 23000.0% in 2025.
  • Tracing GTHP's Gross Profit over 5 years: stood at $41000.0 in 2021, then plummeted by 292.68% to -$79000.0 in 2022, then skyrocketed by 120.25% to $16000.0 in 2023, then plummeted by 112.5% to -$2000.0 in 2024, then surged by 23000.0% to $458000.0 in 2025.
  • Business Quant data shows Gross Profit for GTHP at $458000.0 in Q4 2025, $35000.0 in Q3 2025, and $79000.0 in Q2 2025.